Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]
IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]
Neuroendocrine prostate cancer (NEPC) is a highly aggressive, treatment-resistant form of prostate cancer that emerges after androgen-deprivation therapies fail, leaving few effective options. Memorial Sloan Kettering Cancer Center is now running a Phase I trial testing a radiolabeled antibody called 177Lu-DTPA-SC16.56 in patients with progressive, chemotherapy-relapsed neuroendocrine prostate and lung cancers. DLL3 is the reason […]
FDA has cleared the way for an early clinical trial of a new, off‑the‑shelf cell therapy designed to tackle metastatic castration‑resistant prostate cancer, a late and difficult stage of the disease. The investigational product, referred to in regulatory filings as ADI‑212, is a gene‑edited, “armored” gamma delta CAR T cell therapy that targets prostate‑specific membrane […]
The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]
CRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors. The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 […]
Fifteen years after sipuleucel‑T became the first cellular immunotherapy to show an overall‑survival benefit in metastatic castration‑resistant prostate cancer (mCRPC), a new phase Ib trial at Washington University is testing whether adding the IL‑15 superagonist N‑803 (Anktiva) can turn that modest, durable survival signal into a stronger, more consistent immune attack on metastatic disease. The […]
Bria-PROS+ has received clearance from the U.S. Food and Drug Administration to enter clinical testing as an investigational personalized, off-the-shelf cellular immunotherapy for prostate cancer. The FDA completed its review of the Investigational New Drug application allowing a Phase 1/2a clinical study to move forward. The study is expected to evaluate the safety, tolerability, and […]
A small but encouraging clinical dataset suggests that 67Cu-SAR-bisPSMA may produce substantial anti-tumour activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted multiple treatment options. The findings come from the SECuRE clinical trial, in which 19 participants received treatment with 67Cu-SAR-bisPSMA at an 8 GBq dose. Despite the advanced disease setting, treatment […]
ASP388B is an experimental anticancer drug now being tested in a first-in-human study for people with advanced solid tumors, including mCRPC. The public trial record shows it is being studied both alone and in combination with standard treatments, but its exact molecular target has not been publicly disclosed in the materials I could verify. In […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy